Overview of drug development and regulatory landscape for drugs and cosmetics MCQs With Answer

Overview of drug development and regulatory landscape for drugs and cosmetics MCQs With Answer

This set of multiple-choice questions is designed for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics (MRA201T). It emphasizes the full life-cycle of pharmaceuticals and cosmetics — from discovery, preclinical and clinical development, to regulatory submissions, approvals, post‑marketing surveillance, and compliance with national and international guidelines. Questions cover key regulations (Schedule M, Schedule Y, ICH, CDSCO, FDA), documentation (IND, NDA, CTD, DMF), quality systems (GMP, GLP, GCP), and contemporary topics like biosimilars, pharmacovigilance, and cosmetic safety. Use these MCQs to test conceptual understanding and prepare for professional and university examinations.

Q1. Which document is primarily submitted to regulatory authorities to obtain permission to start clinical trials in humans?

• New Drug Application (NDA)
• Investigational New Drug (IND) application
• Drug Master File (DMF)
• Clinical Trial Report (CTR)

Correct Answer: Investigational New Drug (IND) application

Q2. Which phase of clinical trials focuses mainly on assessing safety, tolerability, pharmacokinetics and pharmacodynamics in a small number of healthy volunteers?

• Phase I
• Phase II
• Phase III
• Phase IV

Correct Answer: Phase I

Q3. The Common Technical Document (CTD) is structured into how many modules for regulatory submission?

• 3 modules
• 4 modules
• 5 modules
• 6 modules

Correct Answer: 5 modules

Q4. Which guideline set focuses on harmonizing pharmaceutical development, quality, safety and efficacy between the US, EU and Japan?

• Good Manufacturing Practice (GMP)
• ICH (International Council for Harmonisation)
• WHO Technical Report Series
• Schedule Y

Correct Answer: ICH (International Council for Harmonisation)

Q5. In India, which schedule of the Drugs and Cosmetics Rules lays down requirements for manufacturing and quality standards (GMP) for pharmaceutical products?

• Schedule D
• Schedule M
• Schedule Y
• Schedule X

Correct Answer: Schedule M

Q6. Which regulatory submission is used to request marketing approval for a new drug after completion of clinical trials?

• Investigational New Drug (IND) application
• Clinical Trial Application (CTA)
• New Drug Application (NDA) / Marketing Authorization Application (MAA)
• Bioequivalence Protocol

Correct Answer: New Drug Application (NDA) / Marketing Authorization Application (MAA)

Q7. What is the primary purpose of a Drug Master File (DMF)?

• To register the drug for marketing
• To provide confidential manufacturer information on facilities, processes or components to regulators
• To report adverse drug reactions
• To summarize clinical trial data

Correct Answer: To provide confidential manufacturer information on facilities, processes or components to regulators

Q8. Which post-marketing activity is principally concerned with detecting, assessing and preventing adverse effects of marketed medicines?

• Good Laboratory Practice (GLP)
• Pharmacovigilance
• Preclinical toxicology
• Bioequivalence testing

Correct Answer: Pharmacovigilance

Q9. Under Schedule Y in India, what is the minimum number of subjects typically required for a Phase III clinical trial to demonstrate efficacy?

• 10–20 subjects
• 50–100 subjects
• Several hundred to a few thousand subjects
• Only animal data is required

Correct Answer: Several hundred to a few thousand subjects

Q10. Which of the following best describes a biosimilar product?

• An identical chemical generic of a small-molecule drug
• A biologic highly similar to an approved reference biologic with no clinically meaningful differences
• A cosmetic ingredient considered safe for topical use
• A dietary supplement with therapeutic claims

Correct Answer: A biologic highly similar to an approved reference biologic with no clinically meaningful differences

Q11. For expedited development, which regulatory pathway allows approval based on surrogate endpoints that reasonably predict clinical benefit?

• Full marketing authorization only
• Accelerated approval / Conditional approval
• Investigational New Drug exemption
• Bioequivalence waiver

Correct Answer: Accelerated approval / Conditional approval

Q12. Which committee must review and approve a clinical trial protocol from an ethical standpoint in India?

• Central Drugs Standard Control Organization (CDSCO)
• Institutional Ethics Committee (IEC) / Independent Ethics Committee (IEC)
• Drug Controller General of India (DCGI)
• National Biodiversity Authority

Correct Answer: Institutional Ethics Committee (IEC) / Independent Ethics Committee (IEC)

Q13. What is a SUSAR in clinical trial safety reporting?

• Suspected Unexpected Serious Adverse Reaction
• Standardized Unified Study Adverse Report
• Summary of Unblinded Safety and Adverse Results
• Scheduled Unexpected Safety Assessment Report

Correct Answer: Suspected Unexpected Serious Adverse Reaction

Q14. Which international guideline specifically addresses quality risk management in pharmaceutical development and manufacture?

• ICH Q9
• ICH E6
• ICH Q1A
• ICH M4

Correct Answer: ICH Q9

Q15. For a generic small-molecule drug approval, the primary requirement demonstrating equivalence is:

• Clinical superiority trials
• Bioequivalence studies showing similar rate and extent of absorption
• Long-term safety studies in thousands of patients
• In vitro dissolution alone without human data

Correct Answer: Bioequivalence studies showing similar rate and extent of absorption

Q16. Which document provides a comprehensive summary of nonclinical pharmacology, toxicology and pharmacokinetics for regulatory review?

• Investigator’s Brochure (IB)
• Clinical Study Report (CSR)
• Nonclinical Overview and Summary in CTD Module 2
• Marketing Authorization Letter

Correct Answer: Nonclinical Overview and Summary in CTD Module 2

Q17. Which regulation governs cosmetics safety and labeling in India under the Drugs & Cosmetics Act?

• Schedule M
• Rule 135 (or relevant cosmetic rules under the Act)
• Schedule Y
• Schedule X

Correct Answer: Rule 135 (or relevant cosmetic rules under the Act)

Q18. What is the primary role of Good Clinical Practice (GCP) guidelines?

• To set manufacturing standards for active pharmaceutical ingredients
• To ensure the rights, safety and well‑being of trial participants and integrity of clinical data
• To regulate advertising of pharmaceuticals and cosmetics
• To provide stability testing requirements for cosmetics only

Correct Answer: To ensure the rights, safety and well‑being of trial participants and integrity of clinical data

Q19. Which of the following is an important regulatory requirement for obtaining import permission for a drug product in India?

• Local clinical trials must always be completed prior to import
• Submission of import license application to CDSCO with manufacturing and quality dossiers
• No documentation is required for import of finished pharmaceuticals
• Only a commercial invoice is sufficient

Correct Answer: Submission of import license application to CDSCO with manufacturing and quality dossiers

Q20. Which study assesses the stability of a drug product under various environmental conditions to establish shelf life and storage conditions?

• Bioequivalence study
• Stability study
• Pharmacokinetic bridging study
• Adverse event monitoring

Correct Answer: Stability study

Download